DT
HealthMore in Health→
Molecule Drives Melanoma Growth and Immune Evasion
Key Takeaways
- Researchers at NYU Langone Health identified HOXD13, a transcription factor that drives melanoma progression through two mechanisms: promoting angiogenesis (blood vessel formation) to fuel tumor growth and suppressing immune system recognition of cancer cells.
- HOXD13's dual functionality—simultaneously enabling tumor expansion while dampening T cell surveillance—explains why melanomas with high HOXD13 activity are particularly aggressive and treatment-resistant.
- Melanomas express varying HOXD13 levels, suggesting that tumors with elevated HOXD13 activity represent a dangerous subset that may require more intensive or targeted therapeutic strategies than standard treatment protocols.
DE
DT Editorial Team··4 min read·via medicalxpress.com